A61K9/0007

Chlorophyllin Containing Pharmaceutical Composition For Prevention Of Pathogenesis Of Coronavirus Disease

Pharmaceutical composition comprises of Chlorophyllin or salts thereof and its utilities including method of treatment, enabling the absorption of Copper-isochlorin e4 into human blood that results in an increase in lymphocyte count and decrease in the abundance of hematopoietic stem and progenitor cells (HPSCs) in human blood. The invention is directed to the treatment of conditions including corona-virus infection, immunosuppression, leucopenia and lymphopenia. The composition disclosed in the invention is thus useful for the treatment of corona virus disease caused by SARS-CoV-2 infection by decreasing viral infection, reducing cytokine storm and pro-inflammatory chemokines, reducing epithelial-cell oxidative-stress in the lungs and increasing the production of leukocytes.

Effervescent formulations comprising dexketoprofen
09717692 · 2017-08-01 ·

The present invention relates to water-soluble formulations comprising the active agent dexketoprofen and to a process for production of said formulations. The present invention also relates to pharmaceutical formulations comprising dexketoprofen which is used in symptomatic treatment of mild to moderate pains such as musculoskeletal pains, dysmenorrhoea, toothache, post-operative pains. The formulations are characterized in being in effervescent form.

METHOD FOR THE PRODUCTION OF A SODIUM ION-FREE EFFERVESCENT TABLET, POWDER OR GRANULATE HAVING A HIGH X ION CONTENT, WHERE X CAN BE A VARIETY OF SUBSTANCES
20170319471 · 2017-11-09 · ·

The process serves for preparing sodium ion-free X carbonate or hydrogencarbonate effervescent powder, such granules or such tablets. The active substances X, at least calcium carbonate, moistened with a small amount of alcohol and water, are mixed as powder with a small amount of lactobionic acid in a partial vacuum in a vacuum tank with continual pumping. As a result, the calcium salt (CaCO.sub.3) of the calcium in the surface layer of the powder particles reacts with the lactobionic acid, effervesces and releases a small amount of CO.sub.2. Consequently, the pressure in the vacuum tank rises and after the end of the effervescent reaction the internal pressure in the vacuum tank drops back to the starting value through the continual pumping. In so doing, the powder dries. After removal from the vacuum chamber an acid, preferably citric acid, as an effervescing agent is added, and subsequently the powder is electively pressed into tablets. The thus produced sodium ion-free calcium carbonate effervescent tablet hence contains at least calcium carbonate as well as citric acid as an effervescing agent, with the pressed particles having been initially effervesced in their surface layer by means of lactobionic acid.

Floating Zinc Gastric Delivery Compositions

A composition includes a therapeutically effective oral pharmaceutical dosage form that becomes buoyant upon contact with gastric fluid. The dosage form includes an active ingredient combination including an amino acid source and a zinc source, an anionic polymer, an effervescent agent, and a pH buffer. The dosage form is effective for releasing the active ingredient combination while buoyant on gastric fluid.

CANNABINOID EMULSION PRODUCT AND PROCESS FOR MAKING THE SAME
20170266127 · 2017-09-21 ·

A dry consumable preparation and related methods are disclosed. The preparation has a bulking agent, and a cannabinoid and/or a cannabinoid extract containing one or more cannabinoids plated onto the bulking agent. The preparation also has an effervescence agent. The effervescence agent has sodium bicarbonate, potassium bicarbonate, and at least one acid, the at least one acid having at least one of citric acid, tartaric acid, or malic acid. The effervescence agent further has a ratio of sodium bicarbonate to potassium bicarbonate to the acid(s) that creates a chemical pH buffering system at a targeted pH range when the dry consumable preparation is added to a targeted amount of water.

Method for decreasing symptoms of alcohol consumption

The present invention relates to methods and compositions of metadoxine and physiologically compatible active derivatives thereof, and their use for decreasing symptoms of alcohol consumption as well as in the prevention of alcohol consumption related symptoms in subjects in need thereof.

EFFERVESCENT COMPOSITION AND METHOD OF MAKING IT

The present disclosure concerns effervescent compositions and methods of making and using the same. In some embodiments, the disclosed effervescent compositions are formed from an input blend comprising an acid and a base by granulating the input blend in a twin-screw processor. The granules formed from the input blend can be formed by an in situ granulating agent, which can be a portion of the acid that melts during granulation. In some embodiments, the effervescent compositions can be made using a twin-screw processor comprising an intake zone for receiving an input blend comprising an acid and a base; a granulation initiation zone for melting only a portion of the acid to serve as an in situ granulating agent; a granulation completion zone for granulating the input blend; and an outlet for discharging the granules.

METHOD, COMPOSITION AND PACKAGE FOR BOWEL CLEANSING
20220233482 · 2022-07-28 ·

The present invention provides a highly palatable colon cleansing formulation that utilizes a low chloride electrolyte-replenishing base solution. When formulated with polyethylene glycol and a selected sugar alcohol, the formulation offers the advantages of superior palatability without undesirable concomitant side effects or a decrease in cleansing efficacy.

SOLID COMPOSITIONS COMPRISING A GLUCOKINASE ACTIVATOR AND METHODS OF MAKING AND USING THE SAME

The invention relates to solid compositions comprising {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid, and methods of making and using such solid compositions.

ESSENTIALLY SODIUM-FREE EFFERVESCENT SOLID PHARMACEUTICAL COMPOSITIONS

Essentially sodium-free effervescent solid pharmaceutical compositions The present invention relates to an effervescent solid pharmaceutical composition, which is essentially free of sodium content, comprising: a therapeutically effective amount of an active pharmaceutical ingredient; one or more pharmaceutically acceptable alkaline earth metal carbonates or hydrogencarbonates in an amount from 1 to 31% by weight of the composition; and one or more pharmaceutically acceptable acids, pharmaceutically acceptable acid salts, or alternatively, a mixture thereof, in an amount from 2 to 62% by weight of the composition; together with one or more pharmaceutically acceptable excipients or carriers; wherein, the total content of the ion sodium in the effervescent solid pharmaceutical composition is equal to or lower than 1 mmol. It also relates to processes for its preparation and its use in therapy.